GlassScriptPhysician profile
Lepercival Griffin
NPI 1558688416
$5,675.72
in general payments reported to CMS, 2019-2025
28 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $913 · 2021: $1,048 · 2022: $558 · 2023: $421 · 2024: $500 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,489.10 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home, Pico 7 |
| Lilly USA, LLC | $713.55 | 2019-2021 | |
| Novo Nordisk INC | $583.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $541.74 | 2019-2023 | Lokelma |
| Organogenesis INC. | $295.42 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $259.59 | 2024-2025 | Nuzyra |
| Abbvie INC. | $255.98 | 2021-2025 | |
| Kerecis Limited | $242.63 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Astellas Pharma US INC | $207.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.13 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $184.25 | 2019-2021 | |
| Allergan, INC. | $178.85 | 2019-2020 | |
| Pfizer INC. | $87.46 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $63.92 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $50.84 | 2025 | |
| Molnlycke Health Care US, LLC | $40.75 | 2022-2023 | Mepilex Border Flex, Exufiber Ag+, Mepilex Border Post-Op Ag |
| Lifenet Health | $39.11 | 2023 | |
| Kci USA, INC. | $32.98 | 2019 | |
| Radius Health, INC. | $26.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.63 | 2021 | |
| Bsn Medical INC | $14.12 | 2019 | |
| Nabriva Therapeutics, Plc | $13.64 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.55 | 2020 | |
| Advanced Oxygen Therapy INC. | $11.82 | 2024 | Topical Oxygen Chamber For Extremities |
| Hollister Incorporated | $11.61 | 2021 | |
| Medline Industries LP | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lepercival Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.